[go: up one dir, main page]

WO2002094187A2 - Novel use - Google Patents

Novel use Download PDF

Info

Publication number
WO2002094187A2
WO2002094187A2 PCT/US2002/015911 US0215911W WO02094187A2 WO 2002094187 A2 WO2002094187 A2 WO 2002094187A2 US 0215911 W US0215911 W US 0215911W WO 02094187 A2 WO02094187 A2 WO 02094187A2
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
compound
pharmaceutically acceptable
conditions
irritable bowel
Prior art date
Application number
PCT/US2002/015911
Other languages
French (fr)
Other versions
WO2002094187A3 (en
Inventor
Douglas William Pierre Hay
Gareth John Sanger
Tadataka Yamada
Original Assignee
Smithkline Beecham Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0112208A external-priority patent/GB0112208D0/en
Priority claimed from GB0129268A external-priority patent/GB0129268D0/en
Priority to AU2002303811A priority Critical patent/AU2002303811B2/en
Priority to HU0400966A priority patent/HUP0400966A2/en
Priority to IL15870102A priority patent/IL158701A0/en
Priority to NZ529462A priority patent/NZ529462A/en
Priority to EP02731870A priority patent/EP1387687A4/en
Priority to CA002447063A priority patent/CA2447063A1/en
Application filed by Smithkline Beecham Corporation filed Critical Smithkline Beecham Corporation
Priority to JP2002590908A priority patent/JP2004534761A/en
Priority to US10/478,272 priority patent/US20040152727A1/en
Priority to MXPA03010509A priority patent/MXPA03010509A/en
Priority to KR10-2003-7014960A priority patent/KR20040016865A/en
Priority to BR0209662-5A priority patent/BR0209662A/en
Publication of WO2002094187A2 publication Critical patent/WO2002094187A2/en
Publication of WO2002094187A3 publication Critical patent/WO2002094187A3/en
Priority to NO20035121A priority patent/NO20035121D0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system

Definitions

  • This invention relates to a novel use, in particular to a use in a method for the treatment and/or prophylaxis of conditions characterised by altered bowel function and/or visceral pain.
  • the mammalian peptide Neurokinin B belongs to the Tachykinin (TK) peptide family which also include Substance P (SP) and Neurokinin A (NKA).
  • TK Tachykinin
  • SP Substance P
  • NKB Neurokinin A
  • NK3 receptor antagonists are known (Drapeau, 1990 Regul. Pept., 31, 125-135), and findings with peptidic NK3 receptor agonists suggest that NKB, by activating the NK3 receptor, has a key role in the modulation of neural input in airways, skin, spinal cord and nigro-striatal pathways (Myers and Undem, 1993, J.Phisiol, 410, 665-679; Counture et al., 1993, Regul. Peptides, 46, 426-429; Mccarson and Krause, 1994, J. Neurosci, 14 (2), 712-720; Arenas et al. 1991, J.Neuroscl, 11, 2332-8).
  • the Rome diagnostic criteria recognise that functional bowel disorder includes the following distinct groups: irritable bowel syndrome (IBS), functional abdominal bloating, functional constipation and functional diarrhea. IBS is generally acknowledged to include discomfort and/or pain along with disorders such as diarrhoea-predominant irritable bowel syndrome, constipation- predominant irritable bowel syndrome and alternater irritable bowel syndrome. (Gut, 1999; 45 (Suppl. II) 1169 -1177). In addition the Rome diagnostic criteria recognise that functional abdominal pain is distinct from functional bowel disorder and that functional abdominal pain includes functional abdominal pain syndrome and unspecified functional abdominal pain.
  • Gastroenterology 1999, 116, 1124-1131 discloses the role of NK3 receptors on responses to colorectal distention in the rat via electrophysiological and behavioral studies.
  • International Patent Application, Publication numbers 98/18762 and 00/21931 disclose certain NK3 receptor antagonists stated to be useful for treating disorders involving NK3 receptors including irritable bowel syndrome (IBS) amongst a list of other disorders.
  • IBS irritable bowel syndrome
  • Certain selective NK3 antagonists are disclosed in International Patent Application, Publication number 95/32948. These compounds are disclosed as having activity in the treatment of: pulmonary disorders (asthma, chronic obstructive pulmonary diseases -COPD-, airway hyperreactivity, cough), skin disorders and itch (for example, atopic dermatitis and cutaneous wheal and flare), neurogenic inflammation and CNS disorders (Parkinson's disease, movement disorders, anxiety and psychosis); and also the treatment of: convulsive disorders (for example epilepsy), renal disorders, urinary incontinence, ocular inflammation, inflammatory pain, eating disorders (food intake inhibition), allergic rhinitis, neurodegenerative disorders (for example Alzheimer's disease), psoriasis, Huntington's disease, and depression.
  • pulmonary disorders asthma, chronic obstructive pulmonary diseases -COPD-, airway hyperreactivity, cough
  • skin disorders and itch for example, atopic dermatitis and cutaneous wheal and flare
  • Compound (I) has activity in the treatment of conditions characterised by altered bowel function and/or visceral pain. This includes, in particular, functional bowel disorders and functional abdominal pain.
  • the functional bowel disorders include particular irritable bowel syndrome conditions, especially, diarrhoea-predominant irritable bowel syndrome, constipation-predominant irritable bowel syndrome and alternater irritable bowel syndrome.
  • Compound (I) has been indicated to be particularly useful for treating diarrhoea-predominant irritable bowel syndrome.
  • the invention provides a method for the treatment and/or prophylaxis of conditions characterised by altered bowel function and/or visceral pain in humans or non-human mammals, which method comprises the administration of an effective, non- toxic and pharmaceutically acceptable amount of an NK3 receptor antagonist, such as Compound (I), or a pharmaceutically acceptable derivative thereof, wherein the condition characterised by altered bowel function and/or visceral pain is selected from certain irritable bowel syndrome conditions, functional abdominal bloating, functional constipation, functional diarrhea, other bowel conditions and functional abdominal pain.
  • an NK3 receptor antagonist such as Compound (I)
  • a pharmaceutically acceptable derivative thereof wherein the condition characterised by altered bowel function and/or visceral pain is selected from certain irritable bowel syndrome conditions, functional abdominal bloating, functional constipation, functional diarrhea, other bowel conditions and functional abdominal pain.
  • the invention provides a method for the treatment and/or prophylaxis of conditions characterised by altered bowel function.
  • the invention provides a method for the treatment and/or prophylaxis of conditions characterised by visceral pain.
  • Suitable conditions characterised by altered bowel function and/or visceral pain are selected from certain irritable bowel syndrome conditions, functional abdominal bloating, functional constipation, functional diarrhea and functional abdominal pain.
  • Particular irritable bowel syndrome conditions include diarrhoea-predominant irritable bowel syndrome, constipation-predominant irritable bowel syndrome and alternater irritable bowel syndrome.
  • a suitable irritable bowel syndrome condition is constipation-predominant irritable bowel syndrome.
  • a suitable irritable bowel syndrome condition is alternater irritable bowel syndrome.
  • a preferred irritable bowel syndrome condition is diarrhoea-predominant irritable bowel syndrome.
  • functional abdominal pain includes functional abdominal pain syndrome and unspecified functional abdominal pain.
  • functional abdominal pain includes functional abdominal pain syndrome.
  • Suitable NK3 antagonists include the compounds specifically and generically disclosed in International Patent Application, Publication number 95/32948 the contents of which are included herein by reference, as if the specific contents of WO 95/32948 were fully set forth herein.
  • a favoured NK3 antagonist is a compound of formula (I):
  • Ar is an optionally substituted phenyl, naphthyl or C5.7 cycloalkdienyl group, or an optionally substituted single or fused ring heterocyclic group, having aromatic character, containing from 5 to 12 ring atoms and comprising up to four hetero-atoms in the or each ring selected from S, O, N;
  • R is linear or branched C- g alkyl, 03.7 cycloalkyl, 04.7 cycloalkylalkyl, optionally substituted phenyl or phenyl C ⁇ g alkyl, an optionally substituted five-membered heteroaromatic ring comprising up to four heteroatom selected from O and N, hydroxy C- g alkyl, amino C ⁇ . alkyl, C ⁇ .g alkylaminoalkyl, di C _ alkylaminoalkyl, C ⁇ . acylaminoalkyl, C ⁇ .g alkoxyalkyl, C . ⁇ alkylcarbonyl, carboxy, C ⁇ alkoxyxcarbonyl, C ⁇ .
  • alkoxycarbonyl C- ⁇ g alkyl, aminocarbonyl, C _6 alkylaminocarbonyl, di Cj.g alkylaminocarbonyl, halogeno ⁇ _ alkyl; or is a group -(CH2)p- when cyclized onto Ar, where p is 2 or 3.
  • Rj and R2 which may be the same or different, are independently hydrogen or C ⁇ _6 linear or branched alkyl, or together form a -(CH2)n- group in which n represents 3, 4, or 5; or R together with R forms a group -(CH2)n-» in which q is 2, 3, 4 or 5;
  • R3 and R4 which may be the same or different, are independently hydrogen, Cj.g linear or branched alkyl, Cj.g alkenyl, aryl, C ⁇ alkoxy, hydroxy, halogen, nitro, cyano, carboxy, carboxamido, sulphonamido, . alkoxycarbonyl, trifluoromethyl, acyloxy, phthalimido, amino, mono- and di-C j .g alkylamino, -O(CH2) r -NT2, in which r is 2, 3, or 4 and T is hydrogen or C _ alkyl or it forms with the adjacent nitrogen a group
  • V and V ⁇ are independently hydrogen or oxygen and u is 0,1 or 2; -O(CH-2) s -OW in which s is 2, 3, or 4 and W is hydrogen or .
  • the invention relates to a method for the treatment and/or prophylaxis of conditions characterised by altered bowel function and/or visceral pain in humans or non-human mammals, which method comprises the administration of an effective, non- toxic and pharmaceutically acceptable amount of a compound of formula (I), or a pharmaceutically acceptable derivative thereof.
  • the invention relates to the treatment and/or prophylaxis of conditions characterised by altered bowel function in particular diarrhoea-predominant irritable bowel syndrome.
  • the invention relates to the treatment and/or prophylaxis of diarrhoea.
  • Ar are phenyl, optionally substituted by hydroxy, halogen, C ⁇ _6 alkoxy or Cj.g alkyl.
  • halogen are chlorine and fluorine, an example of Cj.g alkoxy is methoxy and an example of C . alkyl is methyl.
  • Examples of Ar as a heterocyclic group are thienyl and pyridyl.
  • Examples of Ar as a 05.7 cycloalkdienyl group is cyclohexadienyl.
  • Examples of R are as follows: C j .g alkyl: methyl, ethyl, n-propyl, iso-propyl, n-butyl, heptyl; phenyl C ⁇ _6 alkyl: benzyl; hydroxy C ⁇ _ 6 alkyl: - CH 2 OH, -CH 2 CH 2 OH, CH(Me)OH; amino C ⁇ alkyl: -CH2NH2; di Cj_6 alkylaminoalkyl: -CH2NMe2; C ⁇ _6 alkoxylalkyl: CH 2 OMe; Cj_6 alkylcarbonyl: COMe; C ⁇ . ⁇ alkoxycarbonyl: COOMe; C ⁇ g alkoxycarbon
  • Example of R and R2 as C g alkyl is methyl; example of Rj together with R forming a group-(CH2)q- is spirocyclopentane.
  • R3 and R4 are methyl, ethyl, n-propyl, n-butyl, methoxy, hydroxy, amino, chlorine, fluorine, bromine, acetyloxy, 2-(dimetylamino)ethoxy, 2-(phthalimido)ethoxy, aminoethoxy, 2-(l-pyrrolidinyl)ethoxy, phthalimido, dimethylaminopropoxy, dimethylaminoacetylammo, acetylamino, dimethylaminomethyl and phenyl.
  • R5 are cyclohexyl, phenyl optionally substituted as defined for Ar above; examples of R5 as a heterocyclic group are furyl, thienyl, pyrryl, thiazolyl, benzofuryl and pyridyl.
  • a preferred group of compounds of formula (I) are those in which:
  • Ar is phenyl, optionally substituted by C _ alkyl or halogen; thienyl or a 5-7 cycloalkdienyl group;
  • R is C ⁇ _6 alkyl, C ⁇ _ alkoxycarbonyl, C ⁇ . alkylcarbonyl, hydroxy _ alkyl;
  • R- and R2 are each hydrogen or ⁇ . alkyl;
  • R3 is hydrogen, hydroxy, halogen, Cj.g alkoxy, . alkyl;
  • R4 is hydrogen, C- g alkyl, ⁇ . alkoxy, hydroxy, amino, halogen, aminoalkoxy, mono- or di-alkylaminoalkoxy, mono- or di-alkylaminoalkyl, phthalimidoalkoxy, mono- or di-alkylaminoacylamino and acylamino;
  • R5 is phenyl, thienyl, furyl, pyrryl and thiazolyl.
  • a further preferred group of compounds of formula (I) are those in which:
  • Ar is phenyl, 2-chlorophenyl, 2-thienyl or cyclohexadienyl
  • R is methyl, ethyl, n-propyl, -COOMe, -COMe;
  • R ⁇ and R2 are each hydrogen or methyl
  • R3 is hydrogen, methoxy, or hydroxy
  • R4 is hydrogen, methyl, ethyl, methoxy, hydroxy, amino, chlorine, bromine, dimethylaminoethoxy, 2-(phthalimido)ethoxy, aminoethoxy, 2-(l- pyrrolidinyl)ethoxy, dimethylaminopropoxy, dimethylaminoacetylamino, acetylamino, and dimethylaminomethyl.
  • R5 is phenyl, 2-thienyl, 2-furyl, 2-pyrryl, 2-thiazolyl and 3-thienyl; and X is oxygen.
  • a preferred sub-group of compounds within the scope of formula (I) above is of formula
  • R, R2, R3 and R4 are as defined in formula (I), and Y and Z, which may be the same or different, are each Ar as defined in formula (I).
  • a particularly preferred group of compounds of formula (la) are those of formula (lb) in which the group R is oriented downward and H upward.
  • a most preferred compound of formula (I) is Compound (I).
  • the compounds of formula (I) or their derivatives such as salts or solvates are in pharmaceutically acceptable or substantially pure form.
  • pharmaceutically acceptable form is meant, inter alia, of a pharmaceutically acceptable level of purity excluding normal pharmaceutical additives such as diluents and carriers, and including no material considered toxic at normal dosage levels.
  • a substantially pure form will generally contain at least 50% (excluding normal pharmaceutical additives), preferably 75%, more preferably 90% and still more preferably 95% of the compound of formula (I) or its salt or solvate.
  • One preferred pharmaceutically acceptable form is the crystalline form, including such form in pharmaceutical composition.
  • the additional ionic and solvent moieties must also be non-toxic.
  • suitable pharmaceutically acceptable derivatives include pharmaceutically acceptable salts and/or solvates.
  • pharmaceutically acceptable salts of a compound of formula (I) include the acid addition salts with the conventional pharmaceutical acids, for example maleic, hydrochloric, hydrobromic, phosphoric, acetic, fumaric, salicylic, citric, lactic, mandelic, tartaric, succinic, benzoic, ascorbic, and methanesulphonic.
  • Examples of pharmaceutically acceptable solvates of a compound of formula (I) include hydrates.
  • the compounds of formula (I) may have at least one asymmetric centre and therefore may exist in more than one stereoisomeric form.
  • the treatment of the invention extends to all such forms and to mixtures thereof, including racemates.
  • NK3 antagonists are those disclosed in published patent applications WO99/36424, WO00/39114, WO95/28931, WO96/05203, EP776893, WO98/54191, EP673928, WO94/26735 and WO97/10229.
  • the contents of the above mentioned patent publications are incorporated herein as if each individual publication were specifically and individually incorporated by reference herein as though fully set forth.
  • a particular NK3 antagonist is ([[dichlorophenyl)(trimethoxybenzoy)morpholinyl]ethyl]spiro[benzo(c)thiophenepiperidine] oxide.
  • a particular NK3 antagonist is Rl 13281.
  • a particular NK3 antagonist is N10A.
  • a particular NK3 antagonist is N5A1.
  • a particular NK3 antagonist is SR-142801.
  • a particular NK3 antagonist is SSR-146977.
  • a particular NK3 antagonist is Cam-2425.
  • a particular NK3 antagonist is MDL-105212.
  • the NK3 antagonist is prepared according to known methods for the particular compound chosen, for example compounds of formula (I) and Compound (I) are prepared according to methods disclosed in WO95/32948 or WO99/14196.
  • NK3 antagonists such as Rl 13281, N10A, N5A1, SR-142801, SSR-146977, Cam-2425 and MDL-105212 are prepared, as appropriate, according to published methods for example those disclosed in WO99/36424, WOOO/39114, WO95/28931, WO96/05203, EP776893, WO98/54191, EP673928, WO94/26735 and WO97/10229.
  • the compounds of the method of the invention such as Compound (I), may be converted into their pharmaceutically acceptable acid addition salts by reaction with the appropriate organic or mineral acids.
  • Solvates of the compounds of the method of the invention such as Compound (I), may be formed by crystallization or recrystallization from the appropriate solvent.
  • hydrates may be formed by crystallization or recrystallization from aqueous solutions, or solutions in organic solvents containing water.
  • Pharmaceutically acceptable derivatives of other NK3 antagonists such as
  • Rl 13281, N10A, N5A1, SR-142801, SSR-146977, Cam-2425 and MDL-105212 include, as appropriate, those disclosed in WO99/36424, WOOO/39114, WO95/28931, WO96/05203, EP776893, WO98/54191, EP673928, WO94/26735 and WO97/ 10229.
  • NK3 receptor antagonists are assessed in standard tests indicates that they are of potential therapeutic utility in the treatment of certain clinical conditions characterized by overstimulation of the tachykinin receptors, in particular the conditions disclosed herein.
  • the relevant tests include those disclosed herein.
  • condition characterised by altered bowel function includes diarrhoea-predominant irritable bowel syndrome, constipation-predominant irritable bowel syndrome, alternater irritable bowel syndrome, functional abdominal bloating, functional constipation and functional diarrhea
  • conditions characterised by altered bowel function includes diarrhoea-predominant irritable bowel syndrome.
  • conditions characterised by altered bowel function includes constipation-predominant irritable bowel syndrome.
  • conditions characterised by altered bowel function includes other bowel conditions.
  • other bowel conditions includes conditions presenting with symptoms such as abdominal pain, urgency, bloating, incomplete evacuation and straining, especially urgency, bloating, incomplete evacuation and straining.
  • the present invention also provides a method for the treatment and/or prophylaxis of conditions characterised by altered bowel function and/or visceral pain, in humans or non-human mammals, which method comprises the administration of an effective, non- toxic and pharmaceutically acceptable amount of an NK3 antagonist , such as Compound (I), or a pharmaceutically acceptable derivative thereof
  • an NK3 antagonist such as Compound (I) or a pharmaceutically acceptable derivative thereof, for use in the treatment and/or prophylaxis of conditions characterised by altered bowel function and/or visceral pain.
  • an NK3 antagonist such as Compound (I) or a pharmaceutically acceptable derivative thereof, in the manufacture of a medicament for the treatment and/or prophylaxis of conditions characterised by altered bowel function and/or visceral pain.
  • the condition characterised by altered bowel function and/or visceral pain is selected from certain irritable bowel syndrome conditions, functional abdominal bloating, functional constipation, functional diarrhea, other bowel conditions and functional abdominal pain.
  • the present invention further provides a pharmaceutical composition
  • a pharmaceutical composition comprising an NK3 antagonist, such as a compound of formula (I), or a pharmaceutically acceptable salt thereof or a or pharmaceutically acceptable solvate thereof, and a pharmaceutically acceptable carrier therefor, for the treatment and/or prophylaxis of conditions characterised by altered bowel function and/or visceral pain suitably wherein the condition characterised by altered bowel function and/or visceral pain is selected from certain irritable bowel syndrome conditions, functional abdominal bloating, functional constipation, functional diarrhea, other bowel conditions and functional abdominal pain.
  • Such a medicament, and a composition of this invention may be prepared by admixture of a compound of the invention with an appropriate carrier. It may contain a diluent, binder, filler, disintegrant, flavouring agent, colouring agent, lubricant or preservative in conventional manner.
  • compositions of known agents for treating the conditions may be employed for example as in the preparation of compositions of known agents for treating the conditions.
  • a pharmaceutical composition of the invention is in unit dosage form and in a form adapted for use in the medical or veterinarial fields.
  • preparations may be in a pack form accompanied by written or printed instructions for use as an agent in the treatment of the conditions.
  • the suitable dosage range for the compounds of the invention depends on the compound to be employed and on the condition of the patient. It will also depend, inter alia, upon the relation of potency to absorbability and the frequency and route of administration.
  • the compound or composition of the invention may be formulated for administration by any route, and is preferably in unit dosage form or in a form that a human patient may self-administer it in a single dosage.
  • the composition is suitable for oral, rectal, topical, parenteral, intravenous or intramuscular administration. Preparations may be designed to give slow release of the active ingredient.
  • Compositions may, for example, be in the form of tablets, capsules, sachets, vials, powders, granules, lozenges, reconstitutable powders, or liquid preparations, for example solutions or suspensions, or suppositories.
  • compositions may contain conventional excipients such as binding agents, for example syrup, acacia, gelatin, sorbitol, tragacanth, or polyvinylpyrrolidone; fillers, for example lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycine; tabletting lubricants, for example magnesium stearate; disintegrants, for example starch, polyvinyl-pyrrolidone, sodium starch glycollate or microcrystalline cellulose; or pharmaceutically acceptable setting agents such as sodium lauryl sulphate.
  • binding agents for example syrup, acacia, gelatin, sorbitol, tragacanth, or polyvinylpyrrolidone
  • fillers for example lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycine
  • tabletting lubricants for example magnesium stearate
  • disintegrants for example starch, polyvinyl-pyrrolidone
  • Solid compositions may be obtained by conventional methods of blending, filling, tabletting or the like. Repeated blending operations may be used to distribute the active agent throughout those compositions employing large quantities of fillers.
  • any carrier suitable for formulating solid pharmaceutical compositions may be used, examples being magnesium stearate, starch, glucose, lactose, sucrose, rice flour and chalk. Tablets may be coated according to methods well known in normal pharmaceutical practice, in particular with an enteric coating.
  • the composition may also be in the form of an ingestible capsule, for example of gelatin containing the compound, if desired with a carrier or other excipients.
  • compositions for oral administration as liquids may be in the form of, for example, emulsions, syrups, or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use.
  • Such liquid compositions may contain conventional additives such as suspending agents, for example sorbitol, syrup, methyl cellulose, gelatin, hydroxyethylcellulose, carboxymethylcellulose, aluminium stearate gel, hydrogenated edible fats; emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; aqueous or non-aqueous vehicles, which include edible oils, for example almond oil, fractionated coconut oil, oily esters, for example esters of glycerine, or propylene glycol, or ethyl alcohol, glycerine, water or normal saline; preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid; and if desired conventional flavouring or colour
  • compositions may be formulated, for example for rectal administration as a suppository. They may also be formulated for presentation in an injectable form in an aqueous or non-aqueous solution, suspension or emulsion in a pharmaceutically acceptable liquid, e.g. sterile pyrogen-free water or a parenterally acceptable oil or a mixture of liquids.
  • a pharmaceutically acceptable liquid e.g. sterile pyrogen-free water or a parenterally acceptable oil or a mixture of liquids.
  • the liquid may contain bacteriostatic agents, anti-oxidants or other preservatives, buffers or solutes to render the solution isotonic with the blood, thickening agents, suspending agents or other pharmaceutically acceptable additives.
  • Such forms will be presented in unit dose form such as ampoules or disposable injection devices or in multi- dose forms such as a bottle from which the appropriate dose may be withdrawn or a solid form or concentrate which can be used to prepare an injectable formulation.
  • the active compounds of this invention may also be administered by inhalation, via the nasal or oral routes.
  • administration can be carried out with a spray formulation comprising a compound of the invention and a suitable carrier, optionally suspended in, for example, a hydrocarbon propellant.
  • Preferred spray formulations comprise micronised compound particles in combination with a surfactant, solvent or a dispersing agent to prevent the sedimentation of suspended particles.
  • the compound particle size is from about 2 to 10 microns.
  • a further mode of administration of the active compounds of this invention comprises transdermal delivery utilising a skin-patch formulation.
  • a preferred formulation comprises a compound of the invention dispersed in a pressure sensitive adhesive which adheres to the skin, thereby permitting the compound to diffuse from the adhesive through the skin for delivery to the patient.
  • pressure sensitive adhesives known in the art such as natural rubber or • silicone can be used.
  • the effective dose of compound depends on the particular compound employed, the condition of the patient and on the frequency and route of administration.
  • a unit dose will generally contain from 20 to 1000 mg and preferably will contain from 30 to 500 mg, in particular 50, 100, 150, 200, 250, 300, 350, 400, 450, or 500 mg.
  • the composition may be administered once or more times a day for example 2, 3 or 4 times daily, and the total daily dose for a 70 kg adult will normally be in the range 100 to 3000 mg.
  • the unit dose will contain from 2 to 20 mg of active ingredient and be administered in multiples, if desired, to give the preceding daily dose.
  • Dosages and formulations of particular NK3 antagonists include those disclosed in the above mentioned patent applications.
  • NK3 ligands are determined by their ability to inhibit the binding of the radiolabelled NK3 ligands, [125l]- [Me-Phe ⁇ j-NKB or [ ⁇ Hj-Senktide, to guinea-pig and human NK3 receptors (Renzetti et al, 1991, Neuropeptide, 18, 104-114; Buell et al, 1992, FEBS, 299(1), 90-95; Chung et al, 1994, Biochem. Biophys. Res. Commun., 198(3), 967-972).
  • the binding assays utilized allow the determination of the concentration of the individual compound required to reduce by 50% the [ 125 I]-[Me-Phe 7 ]-NKB and [ 3 H]-Senktide specific binding to NK3 receptor in equilibrium conditions (IC50).
  • Binding assays provide for each compound tested a mean IC50 value of 2-5 separate experiments performed in duplicate or triplicate.
  • the NK 3 - antagonist activity of the compounds of the present invention is determined by their ability to inhibit senktide-induced contraction of the guinea-pig ileum (Maggi et al, 1990, Br. J.
  • Guinea-pig and rabbit in-vitro functional assays provide for each compound tested a mean Kg value of 3- 8 separate experiments, where Kg is the concentration of the individual compound required to produce a 2-fold rightward shift in the concentration-response curve of senktide.
  • Human receptor functional assay allows the determination of the concentration of the individual compound required to reduce by 50% (IC50 values) the Ca ++ mobilization induced by the agonist NKB. In this assay, the compounds of the present invention behave as antagonists.
  • the therapeutic potential of the compounds of the present invention in treating the conditions mentioned above can be assessed using rodent disease models.
  • FIGURES The invention is illustrated, but not limited by, the following experimental data.
  • Figure 1 shows inhibition by Compound (I) of the ascending excitory reflex
  • Figure 2 shows the lack of significant effect of Compound (I) on small intestinal transit in normal non-sensitised animals
  • Figure 3 shows the effect of Compound (I) on small intestinal transit in egg-albumen sensitisation model
  • Figure 4 shows the effect of Compound (I) on rat colorectal sensitivity and tone.
  • Compound (I) at oral doses of 5, 15 and 50 mg/kg produced no marked or statistically significant effects on rat gastric emptying, as determined using the phenol red method.
  • the high doses used in this study are similar to those that exerted intestinal antinociceptive activity (see below) and are consistent with the low affinity of Compound (I) for the rat NK-3 receptor, relative to its higher affinity for the human or guinea-pig variants of this receptor.
  • the reference standard, morphine sulfate administered orally at 20 mg/kg produced a marked and statistically significant decrease in gastric emptying (see Table 1). This effect was expected and demonstrated the validity of the test system.
  • Table 1 Proportion of gastric emptying in rats after administration of Compound (I), morphine sulfate, phenol red and vehicle only
  • Oral administration of Compound (I) at doses of 5, 15 and 50 mg/kg also produced no marked or statistically significant effect on gastrointestinal motility in the rat, as determined using the charcoal meal test.
  • the distance travelled by the charcoal meal in each Compound (I)-treated group was similar to the vehicle-treated group at each tested dose.
  • morphine sulfate at an oral dose of 10 mg/kg produced a marked and statistically significant decrease in gastrointestinal motility compared with the vehicle-treated group (see Table 2). This effect was expected and demonstrated the validity of the test system.
  • the slowEPSP was elicited by high frequency (20 Hz) electrical stimulation for 1 s, applied to a circumferential internodal strand connecting to the ganglion.
  • a baseline slowEPSP was obtained and once it subsided, Compound (I) at a concentration of 0.1 microM was perfused through the preparation. It was perfused continuously and the slowEPSP was tested at various intervals, hi all four neurons there was a decrease of peak amplitude of depolarisation of over 50% when compared with baseline, once the drug had circulated for at least 30 minutes. There was 100% blockade in one neuron and it even revealed an inhibitory post-synaptic potential (IPSP) on stimulation.
  • IIPSP inhibitory post-synaptic potential
  • the other three neurons showed a blockade, based on the amplitude of depolarisation, of 60-80%.
  • Two of the neurons were filled with biocytin and reacted with streptavidin and Texas Red revealing a Dogiel type II morphology on fluorescence microscopy.
  • NK3 receptor antagonism by Compound (I) 15 mg/ kg po. has been shown to inhibit the increase in rat small intestinal transit time evoked by an egg-albumin challenge.

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nutrition Science (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

A method for the treatment and/or prophylaxis of conditions characterised by altered bowel function and/or visceral pain in humans or non-human mammals, which method comprises the administration of an effective, non-toxic and pharmaceutically acceptable amount of an NK3 receptor antagonist, wherein the condition characterised by altered bowel function and/or visceral pain is selected from certain irritable bowel syndrome conditions, functional abdominal bloating, functional constipation, functional diarrhea, other bowel conditions and functional abdominal pain.

Description

Novel Use
This invention relates to a novel use, in particular to a use in a method for the treatment and/or prophylaxis of conditions characterised by altered bowel function and/or visceral pain.
The mammalian peptide Neurokinin B (NKB) belongs to the Tachykinin (TK) peptide family which also include Substance P (SP) and Neurokinin A (NKA). Pharmacological and molecular biological evidence has shown the existence of three subtypes of TK receptor (NKj, NK2 and NK3) and NKB binds preferentially to the NK3 receptor although this and the other tachykinins are relatively promiscuous in terms of their abilities to recognise each of the NK receptors (Maggi et al , 1993, J. Auton. Pharmacol, 13, 23-93).
Selective peptidic NK3 receptor antagonists are known (Drapeau, 1990 Regul. Pept., 31, 125-135), and findings with peptidic NK3 receptor agonists suggest that NKB, by activating the NK3 receptor, has a key role in the modulation of neural input in airways, skin, spinal cord and nigro-striatal pathways (Myers and Undem, 1993, J.Phisiol, 410, 665-679; Counture et al., 1993, Regul. Peptides, 46, 426-429; Mccarson and Krause, 1994, J. Neurosci, 14 (2), 712-720; Arenas et al. 1991, J.Neuroscl, 11, 2332-8). The Rome diagnostic criteria (see Gut, 1999; 45 (Suppl. II) 1143 -1147) recognise that functional bowel disorder includes the following distinct groups: irritable bowel syndrome (IBS), functional abdominal bloating, functional constipation and functional diarrhea. IBS is generally acknowledged to include discomfort and/or pain along with disorders such as diarrhoea-predominant irritable bowel syndrome, constipation- predominant irritable bowel syndrome and alternater irritable bowel syndrome. (Gut, 1999; 45 (Suppl. II) 1169 -1177). In addition the Rome diagnostic criteria recognise that functional abdominal pain is distinct from functional bowel disorder and that functional abdominal pain includes functional abdominal pain syndrome and unspecified functional abdominal pain. Gastroenterology 1999, 116, 1124-1131 discloses the role of NK3 receptors on responses to colorectal distention in the rat via electrophysiological and behavioral studies. International Patent Application, Publication numbers 98/18762 and 00/21931 disclose certain NK3 receptor antagonists stated to be useful for treating disorders involving NK3 receptors including irritable bowel syndrome (IBS) amongst a list of other disorders.
Certain selective NK3 antagonists are disclosed in International Patent Application, Publication number 95/32948. These compounds are disclosed as having activity in the treatment of: pulmonary disorders (asthma, chronic obstructive pulmonary diseases -COPD-, airway hyperreactivity, cough), skin disorders and itch (for example, atopic dermatitis and cutaneous wheal and flare), neurogenic inflammation and CNS disorders (Parkinson's disease, movement disorders, anxiety and psychosis); and also the treatment of: convulsive disorders (for example epilepsy), renal disorders, urinary incontinence, ocular inflammation, inflammatory pain, eating disorders (food intake inhibition), allergic rhinitis, neurodegenerative disorders (for example Alzheimer's disease), psoriasis, Huntington's disease, and depression.
One particular compound disclosed in WO95/32948 is the compound of Example 85 therein being (S)-N-(α-ethylbenzyl)-3-hydroxy-2-phenylquinoline-4-carboxamide (Compound (I)).
It is now surprisingly indicated that Compound (I) has activity in the treatment of conditions characterised by altered bowel function and/or visceral pain. This includes, in particular, functional bowel disorders and functional abdominal pain. The functional bowel disorders include particular irritable bowel syndrome conditions, especially, diarrhoea-predominant irritable bowel syndrome, constipation-predominant irritable bowel syndrome and alternater irritable bowel syndrome. Compound (I) has been indicated to be particularly useful for treating diarrhoea-predominant irritable bowel syndrome.
Accordingly, the invention provides a method for the treatment and/or prophylaxis of conditions characterised by altered bowel function and/or visceral pain in humans or non-human mammals, which method comprises the administration of an effective, non- toxic and pharmaceutically acceptable amount of an NK3 receptor antagonist, such as Compound (I), or a pharmaceutically acceptable derivative thereof, wherein the condition characterised by altered bowel function and/or visceral pain is selected from certain irritable bowel syndrome conditions, functional abdominal bloating, functional constipation, functional diarrhea, other bowel conditions and functional abdominal pain.
Suitably, the invention provides a method for the treatment and/or prophylaxis of conditions characterised by altered bowel function.
Suitably, the invention provides a method for the treatment and/or prophylaxis of conditions characterised by visceral pain.
Suitable conditions characterised by altered bowel function and/or visceral pain are selected from certain irritable bowel syndrome conditions, functional abdominal bloating, functional constipation, functional diarrhea and functional abdominal pain.
Particular irritable bowel syndrome conditions include diarrhoea-predominant irritable bowel syndrome, constipation-predominant irritable bowel syndrome and alternater irritable bowel syndrome.
A suitable irritable bowel syndrome condition is constipation-predominant irritable bowel syndrome.
A suitable irritable bowel syndrome condition is alternater irritable bowel syndrome.
A preferred irritable bowel syndrome condition is diarrhoea-predominant irritable bowel syndrome. Suitably, functional abdominal pain includes functional abdominal pain syndrome and unspecified functional abdominal pain. Favourably, functional abdominal pain includes functional abdominal pain syndrome.
Suitable NK3 antagonists include the compounds specifically and generically disclosed in International Patent Application, Publication number 95/32948 the contents of which are included herein by reference, as if the specific contents of WO 95/32948 were fully set forth herein.
A favoured NK3 antagonist is a compound of formula (I):
Figure imgf000004_0001
or a pharmaceutically acceptable solvate thereof, or a pharmaceutically acceptable salt thereof, wherein:
Ar is an optionally substituted phenyl, naphthyl or C5.7 cycloalkdienyl group, or an optionally substituted single or fused ring heterocyclic group, having aromatic character, containing from 5 to 12 ring atoms and comprising up to four hetero-atoms in the or each ring selected from S, O, N;
R is linear or branched C- g alkyl, 03.7 cycloalkyl, 04.7 cycloalkylalkyl, optionally substituted phenyl or phenyl C^g alkyl, an optionally substituted five-membered heteroaromatic ring comprising up to four heteroatom selected from O and N, hydroxy C- g alkyl, amino C\. alkyl, C^.g alkylaminoalkyl, di C _ alkylaminoalkyl, C\. acylaminoalkyl, C^.g alkoxyalkyl, C .^ alkylcarbonyl, carboxy, C ^ alkoxyxcarbonyl, C\. alkoxycarbonyl C-μg alkyl, aminocarbonyl, C _6 alkylaminocarbonyl, di Cj.g alkylaminocarbonyl, halogeno \_ alkyl; or is a group -(CH2)p- when cyclized onto Ar, where p is 2 or 3.
Rj and R2, which may be the same or different, are independently hydrogen or Cι_6 linear or branched alkyl, or together form a -(CH2)n- group in which n represents 3, 4, or 5; or R together with R forms a group -(CH2)n-» in which q is 2, 3, 4 or 5;
R3 and R4, which may be the same or different, are independently hydrogen, Cj.g linear or branched alkyl, Cj.g alkenyl, aryl, C\^ alkoxy, hydroxy, halogen, nitro, cyano, carboxy, carboxamido, sulphonamido, . alkoxycarbonyl, trifluoromethyl, acyloxy, phthalimido, amino, mono- and di-Cj.g alkylamino, -O(CH2)r-NT2, in which r is 2, 3, or 4 and T is hydrogen or C _ alkyl or it forms with the adjacent nitrogen a group
Figure imgf000005_0001
in which V and V\ are independently hydrogen or oxygen and u is 0,1 or 2; -O(CH-2)s-OW in which s is 2, 3, or 4 and W is hydrogen or . alkyl; hydroxyalkyl, aminoalkyl, mono-or di-alkylaminoalkyl, acylamino, alkylsulphonylamino, aminoacylamino, mono- or di-alkylaminoacylamino; with up to four R3 substituents being present in the quinoline nucleus; or R4 is a group -(CH2)t- when cyclized onto R5 as aryl, in which t is 1, 2, or 3; R5 is branched or linear C\. alkyl, 03.7 cycloalkyl, 04.7 cycloalkylalkyl, optionally substituted aryl, or an optionally substituted single or fused ring heterocyclic group, having aromatic character, containing from 5 to 12 ring atoms and comprising up to four hetero-atoms in the or each ring selected from S, O, N; X is O, S, or N-C≡N. Suitable mammals are humans.
In particular the invention relates to a method for the treatment and/or prophylaxis of conditions characterised by altered bowel function and/or visceral pain in humans or non-human mammals, which method comprises the administration of an effective, non- toxic and pharmaceutically acceptable amount of a compound of formula (I), or a pharmaceutically acceptable derivative thereof.
Suitably, the invention relates to the treatment and/or prophylaxis of conditions characterised by altered bowel function in particular diarrhoea-predominant irritable bowel syndrome.
Preferably, the invention relates to the treatment and/or prophylaxis of diarrhoea. Examples of Ar are phenyl, optionally substituted by hydroxy, halogen, C\_6 alkoxy or Cj.g alkyl. Examples of halogen are chlorine and fluorine, an example of Cj.g alkoxy is methoxy and an example of C . alkyl is methyl.
Examples of Ar as a heterocyclic group are thienyl and pyridyl. Examples of Ar as a 05.7 cycloalkdienyl group is cyclohexadienyl. Examples of R are as follows: Cj.g alkyl: methyl, ethyl, n-propyl, iso-propyl, n-butyl, heptyl; phenyl Cι_6 alkyl: benzyl; hydroxy Cι_6 alkyl: - CH2OH, -CH2CH2OH, CH(Me)OH; amino C β alkyl: -CH2NH2; di Cj_6 alkylaminoalkyl: -CH2NMe2; Cι_6 alkoxylalkyl: CH2OMe; Cj_6 alkylcarbonyl: COMe; C\.β alkoxycarbonyl: COOMe; Cμg alkoxycarbonyl Cμg alkyl: CH2COOMe; Cι_6 alkylaminocarbonyl: CONHMe; di Cι_6 alkylaminocarbonyl: CONMe2, CO(l-pyrrolidinyl); halogen Cι_g alkyl: trifluoromethyl; -(CH2) - when cyclized onto Ar:
Figure imgf000006_0001
Example of R and R2 as C g alkyl is methyl; example of Rj together with R forming a group-(CH2)q- is spirocyclopentane.
Examples of R3 and R4 are methyl, ethyl, n-propyl, n-butyl, methoxy, hydroxy, amino, chlorine, fluorine, bromine, acetyloxy, 2-(dimetylamino)ethoxy, 2-(phthalimido)ethoxy, aminoethoxy, 2-(l-pyrrolidinyl)ethoxy, phthalimido, dimethylaminopropoxy, dimethylaminoacetylammo, acetylamino, dimethylaminomethyl and phenyl.
Examples of R5 are cyclohexyl, phenyl optionally substituted as defined for Ar above; examples of R5 as a heterocyclic group are furyl, thienyl, pyrryl, thiazolyl, benzofuryl and pyridyl. A preferred group of compounds of formula (I) are those in which:
Ar is phenyl, optionally substituted by C _ alkyl or halogen; thienyl or a 5-7 cycloalkdienyl group;
R is Cι_6 alkyl, C}_ alkoxycarbonyl, C\. alkylcarbonyl, hydroxy _ alkyl; R- and R2 are each hydrogen or γ. alkyl; R3 is hydrogen, hydroxy, halogen, Cj.g alkoxy, . alkyl; R4 is hydrogen, C- g alkyl, \. alkoxy, hydroxy, amino, halogen, aminoalkoxy, mono- or di-alkylaminoalkoxy, mono- or di-alkylaminoalkyl, phthalimidoalkoxy, mono- or di-alkylaminoacylamino and acylamino;
R5 is phenyl, thienyl, furyl, pyrryl and thiazolyl. A further preferred group of compounds of formula (I) are those in which:
Ar is phenyl, 2-chlorophenyl, 2-thienyl or cyclohexadienyl;
R is methyl, ethyl, n-propyl, -COOMe, -COMe;
R\ and R2 are each hydrogen or methyl;
R3 is hydrogen, methoxy, or hydroxy;
R4 is hydrogen, methyl, ethyl, methoxy, hydroxy, amino, chlorine, bromine, dimethylaminoethoxy, 2-(phthalimido)ethoxy, aminoethoxy, 2-(l- pyrrolidinyl)ethoxy, dimethylaminopropoxy, dimethylaminoacetylamino, acetylamino, and dimethylaminomethyl.
R5 is phenyl, 2-thienyl, 2-furyl, 2-pyrryl, 2-thiazolyl and 3-thienyl; and X is oxygen. A preferred sub-group of compounds within the scope of formula (I) above is of formula
Figure imgf000007_0001
in which:
R, R2, R3 and R4 are as defined in formula (I), and Y and Z, which may be the same or different, are each Ar as defined in formula (I).
A particularly preferred group of compounds of formula (la) are those of formula (lb) in which the group R is oriented downward and H upward.
Figure imgf000007_0002
A most preferred compound of formula (I) is Compound (I).
The compounds of formula (I) or their derivatives such as salts or solvates are in pharmaceutically acceptable or substantially pure form. By pharmaceutically acceptable form is meant, inter alia, of a pharmaceutically acceptable level of purity excluding normal pharmaceutical additives such as diluents and carriers, and including no material considered toxic at normal dosage levels.
A substantially pure form will generally contain at least 50% (excluding normal pharmaceutical additives), preferably 75%, more preferably 90% and still more preferably 95% of the compound of formula (I) or its salt or solvate. One preferred pharmaceutically acceptable form is the crystalline form, including such form in pharmaceutical composition. In the case of salts and solvates the additional ionic and solvent moieties must also be non-toxic.
As indicated above suitable pharmaceutically acceptable derivatives include pharmaceutically acceptable salts and/or solvates. Examples of pharmaceutically acceptable salts of a compound of formula (I) include the acid addition salts with the conventional pharmaceutical acids, for example maleic, hydrochloric, hydrobromic, phosphoric, acetic, fumaric, salicylic, citric, lactic, mandelic, tartaric, succinic, benzoic, ascorbic, and methanesulphonic.
Examples of pharmaceutically acceptable solvates of a compound of formula (I) include hydrates.
The compounds of formula (I) may have at least one asymmetric centre and therefore may exist in more than one stereoisomeric form. The treatment of the invention extends to all such forms and to mixtures thereof, including racemates.
Other NK3 antagonists are those disclosed in published patent applications WO99/36424, WO00/39114, WO95/28931, WO96/05203, EP776893, WO98/54191, EP673928, WO94/26735 and WO97/10229. The contents of the above mentioned patent publications are incorporated herein as if each individual publication were specifically and individually incorporated by reference herein as though fully set forth. A particular NK3 antagonist is ([[dichlorophenyl)(trimethoxybenzoy)morpholinyl]ethyl]spiro[benzo(c)thiophenepiperidine] oxide. A particular NK3 antagonist is Rl 13281. A particular NK3 antagonist is N10A. A particular NK3 antagonist is N5A1. A particular NK3 antagonist is SR-142801. A particular NK3 antagonist is SSR-146977. A particular NK3 antagonist is Cam-2425. A particular NK3 antagonist is MDL-105212. The NK3 antagonist is prepared according to known methods for the particular compound chosen, for example compounds of formula (I) and Compound (I) are prepared according to methods disclosed in WO95/32948 or WO99/14196. Other NK3 antagonists such as Rl 13281, N10A, N5A1, SR-142801, SSR-146977, Cam-2425 and MDL-105212 are prepared, as appropriate, according to published methods for example those disclosed in WO99/36424, WOOO/39114, WO95/28931, WO96/05203, EP776893, WO98/54191, EP673928, WO94/26735 and WO97/10229.
The compounds of the method of the invention such as Compound (I), may be converted into their pharmaceutically acceptable acid addition salts by reaction with the appropriate organic or mineral acids.
Solvates of the compounds of the method of the invention such as Compound (I), may be formed by crystallization or recrystallization from the appropriate solvent. For example, hydrates may be formed by crystallization or recrystallization from aqueous solutions, or solutions in organic solvents containing water. Pharmaceutically acceptable derivatives of other NK3 antagonists such as
Rl 13281, N10A, N5A1, SR-142801, SSR-146977, Cam-2425 and MDL-105212 include, as appropriate, those disclosed in WO99/36424, WOOO/39114, WO95/28931, WO96/05203, EP776893, WO98/54191, EP673928, WO94/26735 and WO97/ 10229.
The activity of the compounds of the method of the invention such as Compound (I), as NK3 receptor antagonists are assessed in standard tests indicates that they are of potential therapeutic utility in the treatment of certain clinical conditions characterized by overstimulation of the tachykinin receptors, in particular the conditions disclosed herein. The relevant tests include those disclosed herein.
When used herein "conditions characterised by altered bowel function" includes diarrhoea-predominant irritable bowel syndrome, constipation-predominant irritable bowel syndrome, alternater irritable bowel syndrome, functional abdominal bloating, functional constipation and functional diarrhea
In particular conditions characterised by altered bowel function includes diarrhoea-predominant irritable bowel syndrome. In particular conditions characterised by altered bowel function includes constipation-predominant irritable bowel syndrome.
In particular conditions characterised by altered bowel function includes alternater irritable bowel syndrome
In particular conditions characterised by altered bowel function includes other bowel conditions.
When used herein "other bowel conditions" includes conditions presenting with symptoms such as abdominal pain, urgency, bloating, incomplete evacuation and straining, especially urgency, bloating, incomplete evacuation and straining.
The present invention also provides a method for the treatment and/or prophylaxis of conditions characterised by altered bowel function and/or visceral pain, in humans or non-human mammals, which method comprises the administration of an effective, non- toxic and pharmaceutically acceptable amount of an NK3 antagonist , such as Compound (I), or a pharmaceutically acceptable derivative thereof The present invention also provides an NK3 antagonist, such as Compound (I) or a pharmaceutically acceptable derivative thereof, for use in the treatment and/or prophylaxis of conditions characterised by altered bowel function and/or visceral pain. There is also provided the use of an NK3 antagonist, such as Compound (I) or a pharmaceutically acceptable derivative thereof, in the manufacture of a medicament for the treatment and/or prophylaxis of conditions characterised by altered bowel function and/or visceral pain. Suitably wherein the condition characterised by altered bowel function and/or visceral pain is selected from certain irritable bowel syndrome conditions, functional abdominal bloating, functional constipation, functional diarrhea, other bowel conditions and functional abdominal pain.
The present invention further provides a pharmaceutical composition comprising an NK3 antagonist, such as a compound of formula (I), or a pharmaceutically acceptable salt thereof or a or pharmaceutically acceptable solvate thereof, and a pharmaceutically acceptable carrier therefor, for the treatment and/or prophylaxis of conditions characterised by altered bowel function and/or visceral pain suitably wherein the condition characterised by altered bowel function and/or visceral pain is selected from certain irritable bowel syndrome conditions, functional abdominal bloating, functional constipation, functional diarrhea, other bowel conditions and functional abdominal pain. Such a medicament, and a composition of this invention, may be prepared by admixture of a compound of the invention with an appropriate carrier. It may contain a diluent, binder, filler, disintegrant, flavouring agent, colouring agent, lubricant or preservative in conventional manner.
These conventional excipients may be employed for example as in the preparation of compositions of known agents for treating the conditions. Preferably, a pharmaceutical composition of the invention is in unit dosage form and in a form adapted for use in the medical or veterinarial fields. For example, such preparations may be in a pack form accompanied by written or printed instructions for use as an agent in the treatment of the conditions.
The suitable dosage range for the compounds of the invention depends on the compound to be employed and on the condition of the patient. It will also depend, inter alia, upon the relation of potency to absorbability and the frequency and route of administration.
The compound or composition of the invention may be formulated for administration by any route, and is preferably in unit dosage form or in a form that a human patient may self-administer it in a single dosage. Advantageously, the composition is suitable for oral, rectal, topical, parenteral, intravenous or intramuscular administration. Preparations may be designed to give slow release of the active ingredient.
Compositions may, for example, be in the form of tablets, capsules, sachets, vials, powders, granules, lozenges, reconstitutable powders, or liquid preparations, for example solutions or suspensions, or suppositories.
The compositions, for example those suitable for oral administration, may contain conventional excipients such as binding agents, for example syrup, acacia, gelatin, sorbitol, tragacanth, or polyvinylpyrrolidone; fillers, for example lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycine; tabletting lubricants, for example magnesium stearate; disintegrants, for example starch, polyvinyl-pyrrolidone, sodium starch glycollate or microcrystalline cellulose; or pharmaceutically acceptable setting agents such as sodium lauryl sulphate.
Solid compositions may be obtained by conventional methods of blending, filling, tabletting or the like. Repeated blending operations may be used to distribute the active agent throughout those compositions employing large quantities of fillers. When the composition is in the form of a tablet, powder, or lozenge, any carrier suitable for formulating solid pharmaceutical compositions may be used, examples being magnesium stearate, starch, glucose, lactose, sucrose, rice flour and chalk. Tablets may be coated according to methods well known in normal pharmaceutical practice, in particular with an enteric coating. The composition may also be in the form of an ingestible capsule, for example of gelatin containing the compound, if desired with a carrier or other excipients.
Compositions for oral administration as liquids may be in the form of, for example, emulsions, syrups, or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid compositions may contain conventional additives such as suspending agents, for example sorbitol, syrup, methyl cellulose, gelatin, hydroxyethylcellulose, carboxymethylcellulose, aluminium stearate gel, hydrogenated edible fats; emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; aqueous or non-aqueous vehicles, which include edible oils, for example almond oil, fractionated coconut oil, oily esters, for example esters of glycerine, or propylene glycol, or ethyl alcohol, glycerine, water or normal saline; preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid; and if desired conventional flavouring or colouring agents.
The active compounds of this invention may also be administered by a non-oral route. In accordance with routine pharmaceutical procedure, the compositions may be formulated, for example for rectal administration as a suppository. They may also be formulated for presentation in an injectable form in an aqueous or non-aqueous solution, suspension or emulsion in a pharmaceutically acceptable liquid, e.g. sterile pyrogen-free water or a parenterally acceptable oil or a mixture of liquids. The liquid may contain bacteriostatic agents, anti-oxidants or other preservatives, buffers or solutes to render the solution isotonic with the blood, thickening agents, suspending agents or other pharmaceutically acceptable additives. Such forms will be presented in unit dose form such as ampoules or disposable injection devices or in multi- dose forms such as a bottle from which the appropriate dose may be withdrawn or a solid form or concentrate which can be used to prepare an injectable formulation.
The active compounds of this invention may also be administered by inhalation, via the nasal or oral routes. Such administration can be carried out with a spray formulation comprising a compound of the invention and a suitable carrier, optionally suspended in, for example, a hydrocarbon propellant.
Preferred spray formulations comprise micronised compound particles in combination with a surfactant, solvent or a dispersing agent to prevent the sedimentation of suspended particles. Preferably, the compound particle size is from about 2 to 10 microns.
A further mode of administration of the active compounds of this invention comprises transdermal delivery utilising a skin-patch formulation. A preferred formulation comprises a compound of the invention dispersed in a pressure sensitive adhesive which adheres to the skin, thereby permitting the compound to diffuse from the adhesive through the skin for delivery to the patient. For a constant rate of percutaneous absorption, pressure sensitive adhesives known in the art such as natural rubber or • silicone can be used.
As mentioned above, the effective dose of compound depends on the particular compound employed, the condition of the patient and on the frequency and route of administration. A unit dose will generally contain from 20 to 1000 mg and preferably will contain from 30 to 500 mg, in particular 50, 100, 150, 200, 250, 300, 350, 400, 450, or 500 mg. The composition may be administered once or more times a day for example 2, 3 or 4 times daily, and the total daily dose for a 70 kg adult will normally be in the range 100 to 3000 mg. Alternatively the unit dose will contain from 2 to 20 mg of active ingredient and be administered in multiples, if desired, to give the preceding daily dose. Dosages and formulations of particular NK3 antagonists include those disclosed in the above mentioned patent applications.
No unacceptable toxicological effects are expected with the compounds of the method of the invention when administered in accordance with the invention. The activity of the compounds of the present invention, as NK3 ligands, is determined by their ability to inhibit the binding of the radiolabelled NK3 ligands, [125l]- [Me-Phe^j-NKB or [^Hj-Senktide, to guinea-pig and human NK3 receptors (Renzetti et al, 1991, Neuropeptide, 18, 104-114; Buell et al, 1992, FEBS, 299(1), 90-95; Chung et al, 1994, Biochem. Biophys. Res. Commun., 198(3), 967-972).
The binding assays utilized allow the determination of the concentration of the individual compound required to reduce by 50% the [125I]-[Me-Phe7]-NKB and [3H]-Senktide specific binding to NK3 receptor in equilibrium conditions (IC50).
Binding assays provide for each compound tested a mean IC50 value of 2-5 separate experiments performed in duplicate or triplicate. The most potent compounds of the present invention show IC50 values in the range 1-1000 nM; in particular, in guinea-pig cortex membranes by displacement of [*1H]-Senktide, the compounds of the Examples 22, 47, 48, and 85 display K s (nM) of 5.6, 8.8, 12.0 and 4.8 respectively (n=3). The NK3- antagonist activity of the compounds of the present invention is determined by their ability to inhibit senktide-induced contraction of the guinea-pig ileum (Maggi et al, 1990, Br. J. Pharmacol, 101, 996-1000) and rabbit isolated iris sphincter muscle (Hall et al., 1991, Eur. J. Pharmacol, 199, 9-14) and human NK3 receptors-mediated Ca++ mobilization (Mochizuki et al, 1994, J. Biol. Chem., 269, 9651-9658). Guinea-pig and rabbit in-vitro functional assays provide for each compound tested a mean Kg value of 3- 8 separate experiments, where Kg is the concentration of the individual compound required to produce a 2-fold rightward shift in the concentration-response curve of senktide. Human receptor functional assay allows the determination of the concentration of the individual compound required to reduce by 50% (IC50 values) the Ca++ mobilization induced by the agonist NKB. In this assay, the compounds of the present invention behave as antagonists.
For the avoidance of doubt, all publications, including but not limited to patents and patent applications, cited in this specification are herein incorporated by reference as if each individual publication were specifically and individually indicated to be incorporated by reference herein as though fully set forth.
The therapeutic potential of the compounds of the present invention in treating the conditions mentioned above can be assessed using rodent disease models.
The invention is illustrated, but not limited by, the following experimental data. FIGURES
The following is a brief description of the figures referred to below:
Figure 1 : shows inhibition by Compound (I) of the ascending excitory reflex;
Figure 2: shows the lack of significant effect of Compound (I) on small intestinal transit in normal non-sensitised animals;
Figure 3: shows the effect of Compound (I) on small intestinal transit in egg-albumen sensitisation model; and
Figure 4: shows the effect of Compound (I) on rat colorectal sensitivity and tone.
EXPERIMENTAL RESULTS
INABILITY OF COMPOUND (I) TO AFFECT NORMAL GASTROINTESTINAL
MOTILITY
Compound (I) at oral doses of 5, 15 and 50 mg/kg produced no marked or statistically significant effects on rat gastric emptying, as determined using the phenol red method. The high doses used in this study are similar to those that exerted intestinal antinociceptive activity (see below) and are consistent with the low affinity of Compound (I) for the rat NK-3 receptor, relative to its higher affinity for the human or guinea-pig variants of this receptor. By contrast, the reference standard, morphine sulfate administered orally at 20 mg/kg produced a marked and statistically significant decrease in gastric emptying (see Table 1). This effect was expected and demonstrated the validity of the test system.
Table 1: Proportion of gastric emptying in rats after administration of Compound (I), morphine sulfate, phenol red and vehicle only
GROUP ORAL TREATMENT DOSE (mg kg) % GASTRIC
EMPTYING
_
1 Phenol red only -
2 Vehicle - 60.6
3 Compound (I) 5 55.2
4 Compound (I) 15 50.7
5 Compound (I) 50 62.4
6 Morphine sulfate 20 30.8**
Significance of difference from vehicle-treated group: **p < 0.01
Oral administration of Compound (I) at doses of 5, 15 and 50 mg/kg also produced no marked or statistically significant effect on gastrointestinal motility in the rat, as determined using the charcoal meal test. Thus, the distance travelled by the charcoal meal in each Compound (I)-treated group was similar to the vehicle-treated group at each tested dose. By contrast, morphine sulfate at an oral dose of 10 mg/kg produced a marked and statistically significant decrease in gastrointestinal motility compared with the vehicle-treated group (see Table 2). This effect was expected and demonstrated the validity of the test system.
Table 2: Effect of Compound (I), morphine sulfate, and vehicle on gastrointestinal motility in rats, as determined by the charcoal meal test
GROUP ORAL DOSE GROUP MEAN DISTANCE % CHANGE
TREATMENT (mg/kg) TRAVELLED BY CHARCOAL FROM AS % OF TOTAL GUT VEHICLE- LENGTH ± SD TREATED ANIMALS
1 Vehicle - 53.0 + 7.6
2 Compound (I) 5 46.9 + 5.3 -11.5
3 Compound (I) 15 52.1 + 7.1 -1.7
4 Compound (I) 50 50.4 +8.6 -4.9
5 Morphine 10 37.4 + 12.4 -29.4 sulfate
SD - standard deviation
Statistical significance of difference from vehicle-treated group: ** p < 0.01
INHIBITION BY COMPOUND (I) OF SLOW EPSP IN GUINEA-PIG ENTERIC NEURONES
Four neurons were analyzed with Compound (I) to determine its effects on the slowEPSP. The slowEPSP was elicited by high frequency (20 Hz) electrical stimulation for 1 s, applied to a circumferential internodal strand connecting to the ganglion. A baseline slowEPSP was obtained and once it subsided, Compound (I) at a concentration of 0.1 microM was perfused through the preparation. It was perfused continuously and the slowEPSP was tested at various intervals, hi all four neurons there was a decrease of peak amplitude of depolarisation of over 50% when compared with baseline, once the drug had circulated for at least 30 minutes. There was 100% blockade in one neuron and it even revealed an inhibitory post-synaptic potential (IPSP) on stimulation. The other three neurons showed a blockade, based on the amplitude of depolarisation, of 60-80%. Two of the neurons were filled with biocytin and reacted with streptavidin and Texas Red revealing a Dogiel type II morphology on fluorescence microscopy.
INHIBITION BY COMPOUND (I) OF STRETCH-INDUCED REFLEX ACTIVITY IN GUINEA-PIG ISOLATED COLON
For reflex studies, 5-7 cm lengths of colon were suspended in warmed, oxygenated physiological saline, so that an 8 mm metal bar could be inserted into the lumen and connected, via a thread passing through the intestinal wall, to a pulley system which allowed different weights to pull on the bar and distend the intestine. Force transducers were attached to the wall of the colon via small wire hooks, 5 mm either side of the distending bar. Colonic wall distension using 6, 12 or 20 g weights evoked rhythmic contractions oral to the distension and a small relaxation on the anal side. Application of 12 and 20 g weights evoked similar patterns of activity and although the small relaxation on the anal side of the distension seemed more apparent, the oral excitatory response was not different from the effects of the 6 g weight. Compound (I) 250 nM, applied for 30-45 min, reduced the effects of distension in an approximately distension-dependent manner, with the effects being greater at the higher levels of distension (see Figure below). These data suggest that NK, receptor antagonism by Compound (I) reduces ascending and descending reflexes evoked by distension. Since the effects of Compound (I) on enteric reflexes were more apparent at the higher distension weights, NK, receptors and hence, the slow EPSP component of IP AN activity, may be involved to a greater extent in reflexes evoked using intensive and possibly pathological stimuli.
The date are represented in Figure 1 below and show the changes in the ascending excitatory reflex, measured as area under the curve in g.sec, induced by 6, 12 or 20 g distension, in the absence and presence of Compound (I) and after washout.
INHIBITION BY COMPOUND (I) OF THE EGG-ALBUMIN SENSITIZED INCREASE IN RAT SMALL INTESTINAL TRANSIT
Summary and Conclusions
For the first time, NK3 receptor antagonism by Compound (I) 15 mg/ kg po., has been shown to inhibit the increase in rat small intestinal transit time evoked by an egg-albumin challenge. These data strongly support an involvement of the NK3 receptor in pathological (rather than physiological) changes in intestinal function.
Objectives
Increased rat small intestinal transit induced by sensitization to an egg-albumin immune challenge has previously been used to demonstrate the ability of the 5-HT3 receptor antagonist, alosetron, to normalise disturbed patterns of intestinal transit (Clayton NM. Sargent R. Butler A. Gale J. Maxwell MP. Hunt AA. Barrett VJ. Cambridge D. Bountra C. Humphrey PP. The pharmacological properties of the novel selective 5-HT3 receptor antagonist, alosetron, and its effects on normal and perturbed small intestinal transit in the fasted rat. Neurogastroenterology & Motility. 11(3):207-17, 1999 Jun.). Given both the significance of the data with alosetron and the potential interaction between such challenges within the gut and the NK3 receptor (Gay J, Fioramonti J, Garcia- Villar R, Edmonds-Alt X, Bueno L (1999) Gut, 44, 497-503.), the effects of Compound (I) were studied in this model.
Results
Compound (I) 15 mg/ kg po did not significantly affect small intestinal transit in normal, non-sensitised animals (see Figure 2 below). However, in the egg-albumin sensitisation model, the increased transit seen after egg-albumin sensitisation was greatly inhibited by pre-treatment with compound (I) 15 mg/ kg po.,(see Figure 3). Discussion
These data demonstrate, for the first time with Compound (I), that in contrast to the lack of involvement of the NK3 receptor in normal patterns of intestinal motility, this receptor may have significant function in mediating disturbed patterns of motility. Further, these data and the use of this model now makes it possible to correlate the significances of those data obtained in vitro (demonstrated involvement of NK3 receptors in PAN slow EPSP activity; demonstrated ability of NK3 receptor activation to inhibit non-cholinergic excitatory nerve activity in human isolated colon) with in vivo intestinal pathology.
INHIBITION BY COMPOUND (I) OF INTESTINAL NOCICEPTION
In conscious rats, Compound (I) 50 mg/kg, po had a significant antinociceptive effect during distension of the colo-rectal area at 30, 45 and 60 mmHg distension pressures, without affecting colo-rectal tone (see Figure 4 below). Compound (I) 30 mg/kg, po acted similarly, but the effects were statistically significant only at the highest distension pressure. The lowest dose of Compound (I) tested (10 mg kg, po) was without antinociceptive activity.
These data indicate that selective NK-3 receptor antagonism can reduce intestinal sensitivity to noxious distension.

Claims

Claims
1. A method for the treatment and/or prophylaxis of conditions characterised by altered bowel function and/or visceral pain in humans or non-human mammals, which method comprises the administration of an effective, non-toxic and pharmaceutically acceptable amount of an NK3 receptor antagonist, wherein the condition characterised by altered bowel function and/or visceral pain is selected from certain irritable bowel syndrome conditions, functional abdominal bloating, functional constipation, functional diarrhea, other bowel conditions and functional abdominal pain.
2. A method according to claim 1, for the treatment and/or prophylaxis of conditions characterised by altered bowel function.
3. A method according to claim 1, wherein the irritable bowel syndrome condition is diarrhoea-predominant irritable bowel syndrome.
4. A method for the treatment and/or prophylaxis of conditions characterised by altered bowel function and/or visceral pain in humans or non-human mammals, which method comprises the administration of an effective, non-toxic and pharmaceutically acceptable amount of a compound of formula (I):
Figure imgf000019_0001
or a pharmaceutically acceptable solvate thereof, or a pharmaceutically acceptable salt thereof, wherein:
Ar is an optionally substituted phenyl, naphthyl or 05.7 cycloalkdienyl group, or an optionally substituted single or fused ring heterocyclic group, having aromatic character, containing from 5 to 12 ring atoms and comprising up to four hetero-atoms in the or each ring selected from S, O, N; R is linear or branched C-μg alkyl, 03.7 cycloalkyl, 04.7 cycloalkylalkyl, optionally substituted phenyl or phenyl C . alkyl, an optionally substituted five-membered heteroaromatic ring comprising up to four heteroatom selected from O and N, hydroxy C\. alkyl, amino Cι_6 alkyl, C . alkylaminoalkyl, di C . alkylaminoalkyl, \. acylaminoalkyl, C ^ alkoxyalkyl, C _ alkylcarbonyl, carboxy, C _ alkoxyxcarbonyl, _ alkoxycarbonyl C^.g alkyl, aminocarbonyl, C . alkylaminocarbonyl, di C^.g alkylaminocarbonyl, halogeno Cj.g alkyl; or is a group -(CH2)p- when cyclized onto Ar, where p is 2 or 3. Ri and R2, which may be the same or different, are independently hydrogen or C- g linear or branched alkyl, or together form a -(CH2)n- group in which n represents 3, 4, or 5; or R\ together with R forms a group -(CH2)n-, in which q is 2, 3, 4 or 5; R3 and R4, which may be the same or different, are independently hydrogen, C^.g linear or branched alkyl, C\_ alkenyl, aryl, Cι _6 alkoxy, hydroxy, halogen, nitro, cyano, carboxy, carboxamido, sulphonamido, \.^ alkoxycarbonyl, trifluoromethyl, acyloxy, phthalimido, amino, mono- and di-C g alkylamino, -O(CH2)r-NT2, in which r is 2, 3, or 4 and T is hydrogen or Cj.g alkyl or it forms with the adjacent nitrogen a group
Figure imgf000020_0001
in which V and N\ are independently hydrogen or oxygen and u is 0,1 or 2;
-O(CH2)s-OW in which s is 2, 3, or 4 and W is hydrogen or Cι_g alkyl; hydroxyalkyl, aminoalkyl, mono-or di-alkylaminoalkyl, acylamino, alkylsulphonylamino, aminoacylamino, mono- or di-alkylaminoacylamino; with up to four R3 substituents being present in the quinoline nucleus; or R4 is a group -(CH2)t- when cyclized onto R5 as aryl, in which t is 1, 2, or 3;
R5 is branched or linear C . alkyl, 03.7 cycloalkyl, 04.7 cycloalkylalkyl, optionally substituted aryl, or an optionally substituted single or fused ring heterocyclic group, having aromatic character, containing from 5 to 12 ring atoms and comprising up to four hetero-atoms in the or each ring selected from S, O, N; X is O, S, or N-C≡N.
5. A method according to claim 4, for the treatment and/or prophylaxis of conditions characterised by altered bowel function.
6. A method according to claim 4, wherein the irritable bowel syndrome condition is diarrhoea-predominant irritable bowel syndrome.
7. A method according to claim 4, wherein the compound of formula (I) is (S)-N-(α- ethylbenzyl)-3-hydroxy-2-phenylquinoline-4-carboxamide (Compound (I)).
8. A method for the treatment and/or prophylaxis of conditions characterised by altered bowel function and/or visceral pain in humans or non-human mammals, which method comprises the administration of an effective, non-toxic and pharmaceutically acceptable amount of an NK3 antagonist selected from the list consisting of:
( [ [dichlorophenyl) (trimethoxybenzoy)morpholinyl]ethyl] spiro [benzo(c)thiophenepiperidi nejoxide, Rl 13281, N10A, N5A1, SR-142801, SSR-146977, Cam-2425 and MDL- 105212. or, as appropriate, a pharmaceutically acceptable derivative thereof
9. A method according to claim 8, for the treatment and/or prophylaxis of conditions characterised by altered bowel function.
10. A method according to claim 8, wherein the irritable bowel syndrome condition is diarrhoea-predominant irritable bowel syndrome.
PCT/US2002/015911 2001-05-18 2002-05-17 Novel use WO2002094187A2 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
KR10-2003-7014960A KR20040016865A (en) 2001-05-18 2002-05-17 Novel Use
BR0209662-5A BR0209662A (en) 2001-05-18 2002-05-17 Method for the treatment and / or prophylaxis of conditions characterized by altered intestinal function and / or visceral pain in humans or non-human mammals.
JP2002590908A JP2004534761A (en) 2001-05-18 2002-05-17 New use
IL15870102A IL158701A0 (en) 2001-05-18 2002-05-17 Novel use of nk3 receptor antagonist
NZ529462A NZ529462A (en) 2001-05-18 2002-05-17 Use of an NK-3 receptor antagonist in the treatment of conditions characterised by altered bowel function and/or visceral pain
EP02731870A EP1387687A4 (en) 2001-05-18 2002-05-17 Novel use
CA002447063A CA2447063A1 (en) 2001-05-18 2002-05-17 Novel use
AU2002303811A AU2002303811B2 (en) 2001-05-18 2002-05-17 Novel use
HU0400966A HUP0400966A2 (en) 2001-05-18 2002-05-17 Use of nk3 receptor antagonists for treatment and/or prophylaxis of conditions characterized by altered bowel function and/or visceral pain
US10/478,272 US20040152727A1 (en) 2001-05-18 2002-05-17 Novel use
MXPA03010509A MXPA03010509A (en) 2001-05-18 2002-05-17 Novel use.
NO20035121A NO20035121D0 (en) 2001-05-18 2003-11-17 New use

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0112208.4 2001-05-18
GB0112208A GB0112208D0 (en) 2001-05-18 2001-05-18 New use
GB0129268.9 2001-12-06
GB0129268A GB0129268D0 (en) 2001-12-06 2001-12-06 Novel use

Publications (2)

Publication Number Publication Date
WO2002094187A2 true WO2002094187A2 (en) 2002-11-28
WO2002094187A3 WO2002094187A3 (en) 2003-05-30

Family

ID=26246093

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/015911 WO2002094187A2 (en) 2001-05-18 2002-05-17 Novel use

Country Status (19)

Country Link
EP (1) EP1387687A4 (en)
JP (1) JP2004534761A (en)
KR (1) KR20040016865A (en)
CN (1) CN1269483C (en)
AR (1) AR045879A1 (en)
AU (1) AU2002303811B2 (en)
BR (1) BR0209662A (en)
CA (1) CA2447063A1 (en)
CZ (1) CZ20033115A3 (en)
HU (1) HUP0400966A2 (en)
IL (1) IL158701A0 (en)
MX (1) MXPA03010509A (en)
MY (1) MY134211A (en)
NO (1) NO20035121D0 (en)
NZ (1) NZ529462A (en)
PE (1) PE20021067A1 (en)
PL (1) PL367308A1 (en)
TW (1) TWI243678B (en)
WO (1) WO2002094187A2 (en)

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005097077A2 (en) * 2004-03-30 2005-10-20 Smithkline Beecham Corporation Spray dried pharmaceutical compositions
WO2005100997A2 (en) * 2004-04-16 2005-10-27 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with tachykinin receptor 3 (tacr3)
WO2007041479A2 (en) * 2005-09-30 2007-04-12 Smithkline Beecham Corporation Pharmaceutical compositions
EP2088154A1 (en) 2004-03-09 2009-08-12 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7608628B2 (en) 2005-12-12 2009-10-27 Astrazeneca Ab Alkylsulphonamide quinolines
EP2246360A1 (en) 2003-01-28 2010-11-03 Ironwood Pharmaceuticals, Inc. Compositions for the treatment of gastrointestinal disorders
WO2011069038A2 (en) 2009-12-03 2011-06-09 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
WO2013138352A1 (en) 2012-03-15 2013-09-19 Synergy Pharmaceuticals Inc. Formulations of guanylate cyclase c agonists and methods of use
WO2014029983A1 (en) 2012-08-21 2014-02-27 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
WO2014151206A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
EP2810951A2 (en) 2008-06-04 2014-12-10 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2014197720A2 (en) 2013-06-05 2014-12-11 Synergy Pharmaceuticals, Inc. Ultra-pure agonists of guanylate cyclase c, method of making and using same
EP2998314A1 (en) 2007-06-04 2016-03-23 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US9475773B2 (en) 2013-04-19 2016-10-25 Astrazeneca Ab NK3 receptor antagonist compound (NK3RA) for use in a method for the treatment of polycystic ovary syndrome (PCOS)
EP3241839A1 (en) 2008-07-16 2017-11-08 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
WO2018129552A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds useful for treating gastrointestinal tract disorders
WO2018129556A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
WO2018129557A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Inhibitors of nhe-mediated antiport
EP3351248A1 (en) 2008-12-31 2018-07-25 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
US10272079B2 (en) 2013-04-12 2019-04-30 Ardelyx, Inc. NHE3-binding compounds and methods for inhibiting phosphate transport
US10376481B2 (en) 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR200452372Y1 (en) * 2010-05-14 2011-02-22 서일수 Communication line support device of construction lift
KR101034774B1 (en) * 2010-07-30 2011-05-17 (주)챔피온코리아 Lift device using wire rope

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6124316A (en) * 1994-03-18 2000-09-26 Sanofi Compounds which are specific antagonists of the human NK3 receptor and their use as medicinal products and diagnostic tools

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5434158A (en) * 1994-04-26 1995-07-18 Merck & Co., Inc. Spiro-substituted azacycles as neurokinin-3 antagonists
AR004735A1 (en) * 1995-11-24 1999-03-10 Smithkline Beecham Spa CHINOLEIN 4-AMIDO SUBSTITUTED, A PROCEDURE FOR ITS PREPARATION, A PHARMACEUTICAL COMPOSITION THAT CONTAINS THEM AND THE USE OF THE SAME FOR THE PREPARATION OF A MEDICINAL PRODUCT.
JP2002500645A (en) * 1997-05-23 2002-01-08 スミスクライン・ビーチャム・ソシエタ・ペル・アチオニ Quinoline-4-carboxamide derivatives as NK-2 and NK-3 receptor antagonists
NZ511777A (en) * 1998-11-20 2003-12-19 Smithkline Beecham S Quinoline-4-carboxamide derivatives as NK-3 and NK-2 receptor antagonists

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6124316A (en) * 1994-03-18 2000-09-26 Sanofi Compounds which are specific antagonists of the human NK3 receptor and their use as medicinal products and diagnostic tools

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1387687A2 *

Cited By (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2246360A1 (en) 2003-01-28 2010-11-03 Ironwood Pharmaceuticals, Inc. Compositions for the treatment of gastrointestinal disorders
EP2088154A1 (en) 2004-03-09 2009-08-12 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
WO2005097077A2 (en) * 2004-03-30 2005-10-20 Smithkline Beecham Corporation Spray dried pharmaceutical compositions
WO2005097077A3 (en) * 2004-03-30 2006-04-13 Smithkline Beecham Corp Spray dried pharmaceutical compositions
AU2005231355B2 (en) * 2004-03-30 2008-09-18 Smithkline Beecham Corporation Spray dried pharmaceutical compositions
WO2005100997A2 (en) * 2004-04-16 2005-10-27 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with tachykinin receptor 3 (tacr3)
WO2005100997A3 (en) * 2004-04-16 2006-05-18 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with tachykinin receptor 3 (tacr3)
WO2007041479A2 (en) * 2005-09-30 2007-04-12 Smithkline Beecham Corporation Pharmaceutical compositions
WO2007041479A3 (en) * 2005-09-30 2007-10-11 Smithkline Beecham Corp Pharmaceutical compositions
US7608628B2 (en) 2005-12-12 2009-10-27 Astrazeneca Ab Alkylsulphonamide quinolines
US8071621B2 (en) 2005-12-12 2011-12-06 Astrazeneca Ab Alkylsulphonamide quinolines
EP2998314A1 (en) 2007-06-04 2016-03-23 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP2810951A2 (en) 2008-06-04 2014-12-10 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP3241839A1 (en) 2008-07-16 2017-11-08 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
EP3939964A1 (en) 2008-12-31 2022-01-19 Ardelyx, Inc. Combinations for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
EP3351248A1 (en) 2008-12-31 2018-07-25 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
EP2923706A1 (en) 2009-12-03 2015-09-30 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia
WO2011069038A2 (en) 2009-12-03 2011-06-09 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP3708179A1 (en) 2012-03-15 2020-09-16 Bausch Health Ireland Limited Formulations of guanylate cyclase c agonists and methods of use
EP4309673A2 (en) 2012-03-15 2024-01-24 Bausch Health Ireland Limited Formulations of guanylate cyclase c agonists and methods of use
WO2013138352A1 (en) 2012-03-15 2013-09-19 Synergy Pharmaceuticals Inc. Formulations of guanylate cyclase c agonists and methods of use
US10376481B2 (en) 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
WO2014029983A1 (en) 2012-08-21 2014-02-27 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
WO2014151206A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
US10272079B2 (en) 2013-04-12 2019-04-30 Ardelyx, Inc. NHE3-binding compounds and methods for inhibiting phosphate transport
US10940146B2 (en) 2013-04-12 2021-03-09 Ardelyx, Inc. NHE3-binding compounds and methods for inhibiting phosphate transport
US9475773B2 (en) 2013-04-19 2016-10-25 Astrazeneca Ab NK3 receptor antagonist compound (NK3RA) for use in a method for the treatment of polycystic ovary syndrome (PCOS)
WO2014197720A2 (en) 2013-06-05 2014-12-11 Synergy Pharmaceuticals, Inc. Ultra-pure agonists of guanylate cyclase c, method of making and using same
EP4424697A2 (en) 2013-06-05 2024-09-04 Bausch Health Ireland Limited Ultra-pure agonists of guanylate cyclase c, method of making and using same
WO2018129557A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Inhibitors of nhe-mediated antiport
WO2018129556A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
WO2018129552A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds useful for treating gastrointestinal tract disorders
US11147884B2 (en) 2017-01-09 2021-10-19 Ardelyx, Inc. Inhibitors of NHE-mediated antiport
US11242337B2 (en) 2017-01-09 2022-02-08 Ardelyx, Inc. Compounds useful for treating gastrointestinal tract disorders

Also Published As

Publication number Publication date
AU2002303811B2 (en) 2005-07-07
AR045879A1 (en) 2005-11-16
CN1269483C (en) 2006-08-16
NO20035121L (en) 2003-11-17
CZ20033115A3 (en) 2004-09-15
JP2004534761A (en) 2004-11-18
KR20040016865A (en) 2004-02-25
BR0209662A (en) 2004-04-20
PE20021067A1 (en) 2003-02-02
TWI243678B (en) 2005-11-21
CA2447063A1 (en) 2002-11-28
EP1387687A4 (en) 2006-07-05
CN1509175A (en) 2004-06-30
NZ529462A (en) 2005-07-29
NO20035121D0 (en) 2003-11-17
WO2002094187A3 (en) 2003-05-30
IL158701A0 (en) 2004-05-12
MXPA03010509A (en) 2004-03-02
HUP0400966A2 (en) 2004-08-30
PL367308A1 (en) 2005-02-21
EP1387687A2 (en) 2004-02-11
MY134211A (en) 2007-11-30

Similar Documents

Publication Publication Date Title
AU2002303811B2 (en) Novel use
AU2002303811A1 (en) Novel use
JP5923502B2 (en) Use of sigma ligands in opioid-induced hyperalgesia
AU2002351381B2 (en) Method for treating circadian rhythm disruptions
JP6005526B2 (en) Sigma ligands for preventing analgesic effects of opioids and opiates and their dependence in postoperative pain
CA2713930A1 (en) Combined use of angiogenesis inhibitor and taxane
TWI629984B (en) Use of sigma ligands for the prevention and treatment of pain associated to interstitial cystitis/bladder pain syndrome (ic/bps)
JPH11504044A (en) Treatment method and pharmaceutical preparation
AU2009215107B2 (en) Treatments for neuropathy
US8921409B2 (en) Combination of 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1H)-yl]propoxy}benzamide and a NMDA receptor antagonist and pharmaceutical compositions containing the same
CN111601591A (en) Treatment and prevention of sleep disorders
JPH05132430A (en) Use of glycine/nmda receptor ligand relating to therapy of drug dependence and withdrawal symptoms
RU2155754C2 (en) Quinoline derivatives as techychinin nk3 receptor antagonists
US20040152727A1 (en) Novel use
ZA200308415B (en) Novel use.
CA2868228C (en) Treatment of respiratory depression
AU1216299A (en) Quinoline derivatives as tachykinin NK3 receptor antagonists
WO2018197638A1 (en) Novel use of (5r)-5-[5-[{2-[3,5-bis(trifluoromethyl)phenyl]-2-methylpropanoyl}(methyl)amino]-4-(4-fluoro-2-methylphenyl)-2-pyridinyl]-2-methyl-d-prolinamide
AU2013203934A1 (en) Treatments for neuropathy
AU5784501A (en) Quinoline derivatives as tachykinin NK3 receptor antagonists
CN106220562A (en) The new application of two kinds of quinoline ring class medicines
NZ604084B2 (en) New combination between 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1h)-yl]propoxy}benzamide and an nmda receptor antagonist, and pharmaceutical compositions containing it

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002303811

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2002731870

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2003/08415

Country of ref document: ZA

Ref document number: 200308415

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 158701

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 529462

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2447063

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PV2003-3115

Country of ref document: CZ

Ref document number: 1-2003-501170

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/010509

Country of ref document: MX

Ref document number: 1020037014960

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 028101588

Country of ref document: CN

Ref document number: 10478272

Country of ref document: US

Ref document number: 2002590908

Country of ref document: JP

Ref document number: 03101682

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 02004/DELNP/2003

Country of ref document: IN

WWP Wipo information: published in national office

Ref document number: 2002731870

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV2003-3115

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 529462

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 2002303811

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 529462

Country of ref document: NZ